Vistagen TherapeuticsVTGN
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 48 institutions reported holding Vistagen Therapeutics Inc. (VTGN) in their 13F filings, down 8 from Q1 2026. 9 opened new positions and 16 sold out. The largest holders were Commodore Capital LP ($630K), Vanguard Capital Management LLC ($356K) and Two Sigma Investments, LP ($192K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Vistagen Therapeutics Inc.
- CUSIP
- 92840H400
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $691K |
| Exits | 16 | $3.9M |
All 13F filers, Q1 2026 → Q2 2026: 4,715,101 shares bought and 7,669,269 shares sold, net −2,954,168 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 48 holders
| Commodore Capital LP | 0.04% | New | 2,788,620 | $630K |
| Vanguard Capital Management LLC | 0.00% | No change | 1,574,200 | $356K |
| Two Sigma Investments, LP | 0.00% | Add +80.6% | 847,992 | $192K |
| Acadian Asset Management LLC | 0.00% | Add +34.8% | 794,579 | $178K |
| Renaissance Technologies | 0.00% | Add +150.8% | 730,500 | $165K |
| Ikarian Capital, LLC | 0.02% | No change | 519,077 | $117K |
| AdvisorShares Investments LLC | 0.01% | Add +58.3% | 438,643 | $99K |
| Luminus Management LLC | 0.06% | Add +1.8% | 403,115 | $91K |
| Geode Capital Management, LLC | 0.00% | Reduce -19.5% | 365,002 | $83K |
| ADAR1 Capital Management, LLC | 0.00% | Reduce -53.3% | 351,141 | $79K |
| BlackRock, Inc. | 0.00% | Reduce -23.0% | 345,432 | $78K |
| Group One Trading LLC | 0.00% | Add +1431.5% | 304,385 | $69K |
| Verdad Advisers, LP | 0.06% | Add +58.6% | 293,343 | $66K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 217,700 | $49K |
| Jane Street Group, LLC | 0.00% | Reduce -39.6% | 164,827 | $37K |
| Boothbay Fund Management, LLC | 0.00% | No change | 134,571 | $30K |
| State Street Corp. | 0.00% | No change | 121,114 | $27K |
| XTX Topco Ltd | 0.00% | Reduce -22.6% | 118,380 | $27K |
| Northern Trust Corp. | 0.00% | Add +11.2% | 80,823 | $18K |
| Stempoint Capital LP | 0.00% | No change | 616,749 | $17K |
| Citadel Advisors | 0.00% | New | 68,839 | $16K |
| Virtu Financial LLC | 0.00% | New | 66,021 | $15K |
| UBS Group AG | 0.00% | Reduce -26.6% | 57,830 | $13K |
| Gsa Capital Partners LLP | 0.00% | Add +9.5% | 54,584 | $12K |
| Osaic Holdings, Inc. | 0.00% | Add +961.9% | 43,888 | $10K |
| Confluence Wealth Services, Inc. | 0.00% | New | 32,610 | $7K |
| Scientech Research LLC | 0.01% | New | 30,283 | $7K |
| StoneX Group Inc. | 0.00% | Reduce -28.7% | 10,840 | $7K |
| R Squared Ltd | 0.00% | New | 27,745 | $6K |
| Kestra Advisory Services, LLC | 0.00% | No change | 26,000 | $6K |
| HighTower Advisors, LLC | 0.00% | No change | 20,628 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +1053.7% | 18,136 | $4K |
| Bank of America Corp. | 0.00% | New | 16,570 | $4K |
| Truvestments Capital LLC | 0.00% | Reduce -8.6% | 15,540 | $4K |
| Farther Finance Advisors, LLC | 0.00% | New | 15,000 | $3K |
| Raymond James Financial Inc. | 0.00% | Reduce -0.2% | 14,851 | $3K |
| Simplex Trading, LLC | 0.00% | Reduce -84.0% | 14,295 | $3K |
| Deutsche Bank AG | 0.00% | New | 12,000 | $3K |
| Vanguard Global Advisers, LLC | 0.00% | No change | 10,809 | $2K |
| Performa Ltd (US), LLC | 0.00% | Reduce -26.7% | 5,500 | $1K |
| Citigroup Inc. | 0.00% | Add +382100.0% | 3,822 | $864 |
| Jones Financial Companies LLLP | 0.00% | No change | 114 | $80 |
| Morgan Stanley | 0.00% | Add +29700.0% | 298 | $67 |
| SBI Securities Co., Ltd. | 0.00% | Add +0.3% | 289 | $65 |
| JPMorgan Chase & Co. | 0.00% | Add +412.5% | 82 | $62 |
| Fairman Group, LLC | 0.00% | No change | 29 | $7 |
| BNP Paribas Financial Markets | 0.00% | Reduce -53.9% | 6 | $1 |
| Royal Bank of Canada | 0.00% | Reduce -76.5% | 500 | $0 |
"% of holder's portfolio" is VTGN's weight in each manager's 13F, not the share of Vistagen Therapeutics Inc. the manager owns.